IntelliCyt Corp. Introduces new High Throughput Flow Cytometry Screening System
News May 11, 2010
IntelliCyt Corp. has introduced its new High Throughput Flow Cytometry – HTFC™ Screening System at the 25th International Society for Advancement of Cytometry in Seattle.
“By coupling our high-throughput sampler with the large dynamic range and multiplexing capability of flow cytometry-based detectors, the HTFC Screening System provides scientists with powerful advantages over other currently available technologies.”
Designed to enable large scale, high throughput, high content screening, IntelliCyt’s new HTFC Screening System takes a revolutionary approach to cell-based screening by integrating the company’s proprietary HyperCyt® technology and flow cytometry with HyperCytPRO, IntelliCyt’s advanced server-based informatics platform. The result is a screening system that enables researchers to perform broader experiments with more controls and replicates, screen more compounds, and analyze data in ways never before possible with conventional flow cytometry.
Using the HTFC Screening System, researchers can analyze multiparameter cell populations or multiplexed bead suspensions in 96- and 384-well microplates at rates up to 40 wells per minute, capturing data on thousands of cells per second. Because the HTFC Screening system can accommodate very small specimens, sample and reagent requirements are reduced by 50 to 90 percent, resulting in significant cost savings.
The heightened sensitivity and multicolor capabilities of the flow cytometer detection system also enable additional applications, including antibody screening, cytotoxicity studies and biomarker analysis.
“We are grateful to many of our early customers, who have been using earlier versions of our HyperCyt Systems at major pharmaceutical companies, biotechnology companies, and leading academic research organizations. Their feedback led to many of the new powerful and user-friendly features in the HTFC Screening System,” said Dunlay.
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Fructose Formula Poses Risk to Babies With Metabolic DisorderNews
Babies with inherited intolerance of fructose face a risk of acute liver failure if they are fed certain widely available formulas containing fructose, pediatricians and geneticists are warning. Baby formula manufacturers should remove fructose or sucrose, or explicitly label their products to allow parents to avoid those sweeteners if necessary, the doctors say.
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018